Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Evaluation of explant responses to STING ligands: personalized immunosurgical therapy for head and neck squamous cell carcinoma.

Baird JR, Bell RB, Troesch V, Friedman DJ, Bambina S, Kramer G, Blair T, Medler TR, Wu Y, Sun Z, de Gruijl TD, van de Ven R, Leidner R, Crittenden MR, Gough MJ.

Cancer Res. 2018 Sep 17. pii: canres.1652.2018. doi: 10.1158/0008-5472.CAN-18-1652. [Epub ahead of print]

PMID:
30224374
2.

Association of Immunologic Markers With Survival in Upfront Resectable Pancreatic Cancer.

Tang ES, Newell PH, Wolf RF, Hansen PD, Cottam B, Ballesteros-Merino C, Gough MJ.

JAMA Surg. 2018 Aug 8. doi: 10.1001/jamasurg.2018.1757. [Epub ahead of print] No abstract available.

PMID:
30090929
3.

Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.

Crittenden MR, Zebertavage L, Kramer G, Bambina S, Friedman D, Troesch V, Blair T, Baird JR, Alice A, Gough MJ.

Sci Rep. 2018 May 3;8(1):7012. doi: 10.1038/s41598-018-25482-w.

4.

Correction: STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2018 Feb 15;13(2):e0192988. doi: 10.1371/journal.pone.0192988. eCollection 2018.

5.

Amplifying IFN-γ Signaling in Dendritic Cells by CD11c-Specific Loss of SOCS1 Increases Innate Immunity to Infection while Decreasing Adaptive Immunity.

Alice AF, Kramer G, Bambina S, Baird JR, Bahjat KS, Gough MJ, Crittenden MR.

J Immunol. 2018 Jan 1;200(1):177-185. doi: 10.4049/jimmunol.1700909. Epub 2017 Nov 17.

PMID:
29150567
6.

STING expression and response to treatment with STING ligands in premalignant and malignant disease.

Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, Fox BA, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ.

PLoS One. 2017 Nov 14;12(11):e0187532. doi: 10.1371/journal.pone.0187532. eCollection 2017. Erratum in: PLoS One. 2018 Feb 15;13(2):e0192988.

7.

Stimulating Innate Immunity to Enhance Radiation Therapy-Induced Tumor Control.

Baird JR, Monjazeb AM, Shah O, McGee H, Murphy WJ, Crittenden MR, Gough MJ.

Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):362-373. doi: 10.1016/j.ijrobp.2017.04.014. Epub 2017 Apr 19. Review.

PMID:
28871985
8.

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.

Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. doi: 10.1158/1078-0432.CCR-16-2677. Epub 2017 Aug 28.

PMID:
28855348
9.

Erratum to 'Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy' [Oral Oncol. 61 (2016) 166-176].

Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2017 Mar;66:e3. doi: 10.1016/j.oraloncology.2017.02.001. Epub 2017 Feb 12. No abstract available.

PMID:
28202215
10.

Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.

McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr, Gough MJ, Raber J.

Oncotarget. 2017 Feb 7;8(6):9155-9173. doi: 10.18632/oncotarget.13551.

11.

Perceptions About the Present and Future of Surgical Simulation: A National Study of Mixed Qualitative and Quantitative Methodology.

Yiasemidou M, Glassman D, Tomlinson J, Song D, Gough MJ.

J Surg Educ. 2017 Jan - Feb;74(1):108-116. doi: 10.1016/j.jsurg.2016.07.011. Epub 2016 Sep 8.

PMID:
27617919
12.

Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy.

Bryan RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, Fox BA, Crittenden MR, Leidner RS, Curti B.

Oral Oncol. 2016 Oct;61:166-76. doi: 10.1016/j.oraloncology.2016.08.020. Epub 2016 Sep 7. Review. Erratum in: Oral Oncol. 2017 Mar;66:e3.

PMID:
27614589
13.

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy.

Crittenden MR, Baird J, Friedman D, Savage T, Uhde L, Alice A, Cottam B, Young K, Newell P, Nguyen C, Bambina S, Kramer G, Akporiaye E, Malecka A, Jackson A, Gough MJ.

Oncotarget. 2016 Nov 29;7(48):78653-78666. doi: 10.18632/oncotarget.11823.

14.

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma.

Crocenzi T, Cottam B, Newell P, Wolf RF, Hansen PD, Hammill C, Solhjem MC, To YY, Greathouse A, Tormoen G, Jutric Z, Young K, Bahjat KS, Gough MJ, Crittenden MR.

J Immunother Cancer. 2016 Aug 16;4:45. doi: 10.1186/s40425-016-0149-6. eCollection 2016.

15.

Programmed cell death-1 blockade enhances response to stereotactic radiation in an orthotopic murine model of hepatocellular carcinoma.

Friedman D, Baird JR, Young KH, Cottam B, Crittenden MR, Friedman S, Gough MJ, Newell P.

Hepatol Res. 2017 Jun;47(7):702-714. doi: 10.1111/hepr.12789. Epub 2016 Sep 22.

PMID:
27501850
16.

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR.

PLoS One. 2016 Jun 9;11(6):e0157164. doi: 10.1371/journal.pone.0157164. eCollection 2016.

17.

Correlation between experience targets and competence for general surgery certification.

De Siqueira JR, Gough MJ.

Br J Surg. 2016 Jun;103(7):921-7. doi: 10.1002/bjs.10145. Epub 2016 Apr 6.

PMID:
27060772
18.

Stromal fibroblasts support dendritic cells to maintain IL-23/Th17 responses after exposure to ionizing radiation.

Malecka A, Wang Q, Shah S, Sutavani RV, Spendlove I, Ramage JM, Greensmith J, Franks HA, Gough MJ, Saalbach A, Patel PM, Jackson AM.

J Leukoc Biol. 2016 Aug;100(2):381-9. doi: 10.1189/jlb.3A1015-474R. Epub 2016 Apr 5.

19.

OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.

Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, Fox BA, Weinberg AD, Urba WJ.

Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.

PMID:
26614363
20.

Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma.

Bell RB, Leidner R, Feng Z, Crittenden MR, Gough MJ, Fox BA.

J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S107-15. doi: 10.1016/j.joms.2015.05.026. Review. No abstract available.

PMID:
26608138
21.

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.

Baird JR, Friedman D, Cottam B, Dubensky TW Jr, Kanne DB, Bambina S, Bahjat K, Crittenden MR, Gough MJ.

Cancer Res. 2016 Jan 1;76(1):50-61. doi: 10.1158/0008-5472.CAN-14-3619. Epub 2015 Nov 13.

22.

Comparing equals when evaluating immunotherapy with different doses and fractions of radiation therapy.

Gough MJ, Crittenden MR, Young KH.

Immunotherapy. 2015;7(8):847-9. doi: 10.2217/IMT.15.58. Epub 2015 Aug 13. No abstract available.

PMID:
26268988
23.

Attitudes towards the surgical safety checklist and factors associated with its use: A global survey of frontline medical professionals.

Vohra RS, Cowley JB, Bhasin N, Barakat HM, Gough MJ; Schoolofsurgery.org.

Ann Med Surg (Lond). 2015 Apr 20;4(2):119-23. doi: 10.1016/j.amsu.2015.04.001. eCollection 2015 Jun.

24.

Tumor immune remodeling by TGFβ inhibition improves the efficacy of radiation therapy.

Young KH, Gough MJ, Crittenden M.

Oncoimmunology. 2014 Sep 14;4(3):e955696. eCollection 2015 Mar.

25.

TGFβ inhibition prior to hypofractionated radiation enhances efficacy in preclinical models.

Young KH, Newell P, Cottam B, Friedman D, Savage T, Baird JR, Akporiaye E, Gough MJ, Crittenden M.

Cancer Immunol Res. 2014 Oct;2(10):1011-22. doi: 10.1158/2326-6066.CIR-13-0207. Epub 2014 Jul 21.

26.

Expression of arginase I in myeloid cells limits control of residual disease after radiation therapy of tumors in mice.

Crittenden MR, Savage T, Cottam B, Baird J, Rodriguez PC, Newell P, Young K, Jackson AM, Gough MJ.

Radiat Res. 2014 Aug;182(2):182-90. doi: 10.1667/RR13493.1. Epub 2014 Jul 3.

PMID:
24992164
27.

The challenges of implementing a simulation-based surgical training curriculum.

Kordowicz AG, Gough MJ.

Br J Surg. 2014 Apr;101(5):441-3. doi: 10.1002/bjs.9370. Epub 2014 Feb 26. No abstract available.

PMID:
24615294
28.

The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumor.

Crittenden MR, Savage T, Cottam B, Bahjat KS, Redmond WL, Bambina S, Kasiewicz M, Newell P, Jackson AM, Gough MJ.

PLoS One. 2013 Jul 25;8(7):e69527. doi: 10.1371/journal.pone.0069527. Print 2013.

29.

The impact of the myeloid response to radiation therapy.

Gough MJ, Young K, Crittenden M.

Clin Dev Immunol. 2013;2013:281958. doi: 10.1155/2013/281958. Epub 2013 Apr 7. Review.

30.

The ataxia telangiectasia mutated kinase pathway regulates IL-23 expression by human dendritic cells.

Wang Q, Franks HA, Lax SJ, El Refaee M, Malecka A, Shah S, Spendlove I, Gough MJ, Seedhouse C, Madhusudan S, Patel PM, Jackson AM.

J Immunol. 2013 Apr 1;190(7):3246-55. doi: 10.4049/jimmunol.1201484. Epub 2013 Mar 4.

31.

Children's surgery: a national survey of consultant clinical practice.

Mason DG, Shotton H, Wilkinson KA, Gough MJ, Alleway R, Freeth H, Mason M.

BMJ Open. 2012 Oct 17;2(5). pii: e001639. doi: 10.1136/bmjopen-2012-001639. Print 2012.

32.
33.

Expression of NF-κB p50 in tumor stroma limits the control of tumors by radiation therapy.

Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, Gough MJ.

PLoS One. 2012;7(6):e39295. doi: 10.1371/journal.pone.0039295. Epub 2012 Jun 28.

34.
35.

Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy.

Gough MJ, Killeen N, Weinberg AD.

Immunology. 2012 Aug;136(4):437-47. doi: 10.1111/j.1365-2567.2012.03600.x.

36.

Comparative stability of sodium tetradecyl sulphate (STD) and polidocanol foam: impact on vein damage in an in-vitro model.

McAree B, Ikponmwosa A, Brockbank K, Abbott C, Homer-Vanniasinkam S, Gough MJ.

Eur J Vasc Endovasc Surg. 2012 Jun;43(6):721-5. doi: 10.1016/j.ejvs.2012.02.026. Epub 2012 Apr 15.

37.

Immune system plays an important role in the success and failure of conventional cancer therapy.

Gough MJ, Crittenden MR.

Immunotherapy. 2012 Feb;4(2):125-8. doi: 10.2217/imt.11.157. No abstract available.

38.

Comments regarding 'The war against error: a 15 year experience of completion angioscopy following carotid endarterectomy'.

Gough MJ.

Eur J Vasc Endovasc Surg. 2012 Feb;43(2):146. doi: 10.1016/j.ejvs.2011.11.001. Epub 2011 Nov 25. No abstract available.

39.

A strategy to meet the 'two-week' target for carotid endarterectomy in symptomatic patients.

Abbas K, Vohra RS, Salhab M, Sinclair MD, Kent PJ, Gough MJ.

Clin Med (Lond). 2011 Oct;11(5):452-5.

PMID:
22034704
40.

Preprocedural imaging strategies in symptomatic carotid artery stenosis.

Gough MJ.

J Vasc Surg. 2011 Oct;54(4):1215-8. doi: 10.1016/j.jvs.2011.05.101. Epub 2011 Aug 25. Review.

41.

Comments regarding 'the role of cerebral oximetry in combination with awake testing in patients undergoing carotid endarterectomy under local anaesthesia'.

Gough MJ.

Eur J Vasc Endovasc Surg. 2011 May;41(5):606. doi: 10.1016/j.ejvs.2011.01.023. Epub 2011 Mar 8. No abstract available.

42.

Endovenous laser ablation (EVLA) to treat recurrent varicose veins.

Theivacumar NS, Gough MJ.

Eur J Vasc Endovasc Surg. 2011 May;41(5):691-6. doi: 10.1016/j.ejvs.2011.01.018. Epub 2011 Feb 26.

43.

Signaling through OX40 enhances antitumor immunity.

Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA.

Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Review.

44.

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.

Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, Hu HM, Redmond WL, Holland J, Weinberg AD.

J Immunother. 2010 Oct;33(8):798-809. doi: 10.1097/CJI.0b013e3181ee7095.

45.

Comment on "PTFE bypass to below-knee arteries: distal vein collar or not? A prospective randomised multicentre study".

Gough MJ.

Eur J Vasc Endovasc Surg. 2010 Oct;40(4):540; author reply 540-2. doi: 10.1016/j.ejvs.2010.07.002. Epub 2010 Aug 6. No abstract available.

46.

Combination approaches to immunotherapy: the radiotherapy example.

Gough MJ, Crittenden MR.

Immunotherapy. 2009 Nov;1(6):1025-37. doi: 10.2217/imt.09.64. Review.

PMID:
20635917
47.

Cost-effectiveness analysis of general anaesthesia versus local anaesthesia for carotid surgery (GALA Trial).

Gomes M, Soares MO, Dumville JC, Lewis SC, Torgerson DJ, Bodenham AR, Gough MJ, Warlow CP; GALA Collaborative Group.

Br J Surg. 2010 Aug;97(8):1218-25. doi: 10.1002/bjs.7110.

PMID:
20602498
48.

Comment on: Changes required to improve CEA outcomes.

Gamie Z, Wood F, Vohra RS, Gough MJ.

Ann R Coll Surg Engl. 2010 Mar;92(2):173. doi: 10.1308/003588410X12628812459175. No abstract available.

49.

Comments regarding 'PTFE bypass to below-knee arteries: distal vein collar or not? A prospective randomised multicentre study'.

Gough MJ.

Eur J Vasc Endovasc Surg. 2010 Jun;39(6):755. doi: 10.1016/j.ejvs.2010.03.001. Epub 2010 Mar 26. No abstract available.

50.

The impact of different concentrations of sodium tetradecyl sulphate and initial balloon denudation on endothelial cell loss and tunica media injury in a model of foam sclerotherapy.

Ikponmwosa A, Abbott C, Graham A, Homer-Vanniasinkam S, Gough MJ.

Eur J Vasc Endovasc Surg. 2010 Mar;39(3):366-71. doi: 10.1016/j.ejvs.2009.12.025. Epub 2010 Jan 18.

Supplemental Content

Loading ...
Support Center